12/27/2012

The draft guidance details how drugmakers can use clinical trial enrichment to improve the chances that studies will accurately demonstrate effectiveness, writes Deputy Director of Clinical Science Dr. Bob Temple of the FDA's Center for Drug Evaluation and Research.

Full Story:
FDA Voice blog

Related Summaries